logo
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
EN 简
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us

Newsroom

  • Home -
  • Newsroom -
18
Aug 2022
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology
Aug 18, 2022
01
Aug 2022
CARsgen Appoints Dr. Hua Jiang as Executive Director
Aug 01, 2022
19
Jul 2022
Haematologica Publishes Results from the Investigator-Initiated Trials of CARsgen's CT053 BCMA CAR T-Cell Therapy in Multiple Myeloma
Jul 19, 2022
06
Jun 2022
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
Jun 06, 2022
10
May 2022
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen’s CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
May 10, 2022
28
Apr 2022
CARsgen to Present Two Clinical Trials of CT041 at ASCO Annual Meeting
Apr 28, 2022
08
Apr 2022
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
Apr 08, 2022
23
Mar 2022
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies
Mar 23, 2022
23
Mar 2022
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China
Mar 23, 2022
03
Mar 2022
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
Mar 03, 2022
  • 1
  • ...
  • 5
  • 6
  • 7
  • ...
  • 9
Wechat
qr
Linkedin
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
Privacy Policy Terms of Use Developed by Euroland IR
Copyright ©2021-2025 CARsgen Therapeutics Holdings Limited